Saw palmetto for the treatment of men with lower urinary tract symptoms

Journal of Urology

Volumn 163, Issue 5, 2000, Pages 1408-1412

  Gerber, Glenn S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Medicine, herbal; Prostate; Prostatic hyperplasia; Urologic diseases

Indexed keywords

ADRENERGIC RECEPTOR; ADRENERGIC RECEPTOR BLOCKING AGENT; ALFUZOSIN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; FINASTERIDE; PLACEBO; PRAZOSIN; PROSTATE SPECIFIC ANTIGEN; SABAL EXTRACT; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE;

CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; MALE; META ANALYSIS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; URINARY TRACT DISEASE; URINE FLOW RATE; URODYNAMICS;

EID: 0034048759     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)67631-8     Document Type: Review

References (69)

1. Eisenberg, D. M., Kessler, R. C., Foster, C. et al: Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med, 328: 246, 1993
2. Marwick, C.: Growing use of medicinal botanicals forces assessment by drug regulators. JAMA, 273: 607, 1995
3. Ernst, E.: Harmless herbs? A review of the recent literature. Am J Med, 104: 170, 1998
4. Wilt, T. J., Ishani, A., Stark, G. et al: Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA, 280: 1604, 1998
5. Int Med World Report 13: 8, 1998
6. Astin, J. A.: Why patients use alternative medicine: results of a national study. JAMA, 279: 1548, 1998
7. Vincent, C. and Furnham, A.: Why do patients turn to complementary medicine? An empirical study. Br J Clin Psychol, 35: 37, 1996
8. Furnham, A. and Forey, J.: The attitudes, behaviors, and beliefs of patients of conventional vs. complementary (alternative) medicine. J Clin Psychol, 50: 458, 1994
9. Lowe, F. C. and Ku, J. C.: Phytotherapy in treatment of benign prostatic hyperplasia: a critical review. Urology, 48: 12, 1996
10. Bales, G. T., Christiano, A. P., Kirsh, E. J. et al: Phytotherapeutic agents in the treatment of lower urinary tract symptoms: a demographic analysis of awareness and use at the University of Chicago. Urology, 54: 86, 1999
11. Angell, M. and Kassirer, J. P.: Alternative medicine - the risks of untested and unregulated remedies. N Engl J Med, 339: 839, 1998
12. DiPaola, R. S., Zhang, H., Lambert, G. H. et al: Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med, 339: 785, 1998
13. Prasad, K. N., Hernandez, C., Edwards-Prasad, J. et al: Modification of the effect of tamoxifen, cisplatin, DTIC, and interferon-alpha2b on human melanoma cells in culture by a mixture of vitamins. Nutr Cancer, 22: 233, 1994
14. LoVecchio, F., Curry, S. C. and Bagnasco, T.: Butyrolactone-induced central nervous system depression after ingestion of RenewTrient, a "dietary supplement". N Engl J Med, 339: 847, 1998
15. Lowe, F. C., Dreikorn, K., Borkowski, A. et al: Review of recent placebo-controlled trials utilizing phytotherapeutic agents for treatment of BPH. Prostate, 37: 187, 1998
16. Buck, A. C.: Phytotherapy for the prostate. Br J Urol, 78: 325, 1996
17. Nickel, J. C.: Placebo therapy of benign prostatic hyperplasia: a 25-month study. Canadian PROSPECT Study Group. Br J Urol, 81: 383, 1998
18. Barry, M. J., Fowler, F. J., Jr., Bin, L. et al: The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. J Urol, 157: 10, 1997
19. Lowe, F. C.: Editorial Comment. Urology, 51: 1007, 1998
20. Gerber, G. S., Zagaja, G. P., Bales, G. T. et al: Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms: effects on urodynamic parameters and voiding symptoms. Urology, 51: 1003, 1998
21. Mowrey, D. B.: Herbal Tonic Therapies. New Canaan, Connecticut: Keats Publishing, pp. 355-358, 1993
22. Cui, J., Garle, M., Eneroth, P. et al: What do commercial ginseng preparations contain? Lancet, 344: 134, 1994
23. Plosker, G. L. and Brogden, R. N.: Serenoa repens (Permixon). A review of is pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging, 9: 379, 1996
24. DiSilverio, F., Flammia, G. P., Sciarra, A. et al: Plant extracts in BPH. Minerva Urol Nefrol, 45: 143, 1993
25. Carraro, J. C., Raynaud, J. P., Koch, G. et al: Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostatic hyperplasia: a randomized international study of 1,098 patients. Prostate, 29: 231, 1996
26. Iehle, C., Delos, S., Guirou, O. et al: Human prostatic steroid 5 alpha-reductase isoforms - a comparative study of selective inhibitors. J Steroid Biochem Mol Biol, 54: 273, 1995
27. Russell, R. S. and Wilson, J. D.: Steroid 5-alpha-reductase: two genes/two enzymes. Ann Rev Biochem, 63: 25, 1994
28. Span, P. N., Voller, M. C. W. , Smals, A. G. H. et al: Selectivity of finasteride as an in vivo inhibitor of 5-alpha reductase isozyme enzymatic activity in the human prostate. J Urol, 161: 332, 1999
29. Gormley, G. J., Stoner, E., Bruskewitz, R. C. et al: The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med, 327: 1185, 1992
30. Rhodes, L., Primka, R. L., Herman, C. et al: Comparison of finasteride (Proscar), a 5-alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5-alpha reductase inhibition. Prostate, 22: 43, 1993
31. Thigpen, A. E., Silver, R. I., Guileyardo, J. M. et al: Tissue distribution and ontogeny of steroid 5-alpha reductase isozyme expression. J Clin Invest, 92: 903, 1993
32. Span, P. N., Benraad, Th. J., Sweep, A. G. H. et al: Kinetic analysis of steroid 5-alpha-reductase activity at neutral pH in benign prostatic hyperplastic tissue: evidence for type I isozyme activity in the human prostate. J Steroid Biochem Mol Biol, 57: 103, 1996
33. Patel, S., Einstein, M., Geissler, W. et al.: Immunohistochemical analysis of steroid 5-alpha-reductase type 1 in human scalp and prostate. Ann NY Acad Sci, 784: 27, 1996
34. Weisser, H., Tunn, S., Behnke, B. et al: Effects of the Sabal serrulata extract IDS 89 and its subfractions on 5 alpha-reductase activity in human benign prostatic hyperplasia. Prostate, 28: 300, 1996
35. Délos, S., Iehlé, C., Carsol, J.-L. et al: Inhibition of human prostatic testosterone metabolism by a lipido-sterol extract of Serenoa repens (Permixon). J Urol, 155: 572A, abstract 1046, 1996
36. Strauch, G., Perles, P., Vergult, G. et al: Comparison of finasteride (Proscar) and Serenoa repens (Permixon) in the inhibition of 5-alpha reductase in healthy male volunteers. Eur Urol, 26: 247, 1994
37. Di Silverio, F., Monti, S., Sciarra, A. et al: Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate, 37: 77, 1998
38. Sultan, C., Terraza, A., Devillier, C. et al: Inhibition of androgen metabolism and binding by a liposterolic extract of "Serenoa repens B" in human foreskin fibroblasts. J Steroid Biochem, 20: 515, 1984
39. Carilla, E., Briley, M., Fauran, F. et al: Binding of Permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate. J Steroid Biochem, 20: 521, 1984
40. Ravenna, L., DiSilverio, F., Russo, M. A. et al: Effects of the lipidosterolic extract of Serenoa repens (Permixon) on human prostatic cell lines. Prostate, 29: 219, 1996
41. Paubert-Braquet, M., Richardson, F. O., Servent-Saez, N. et al: Effect of Serenoa repens extract (Permixon) on estradiol/ testosterone-induced experimental prostate enlargement in the rat. Pharmacol Res, 34: 171, 1996
42. Casarosa, C., Cosci di Coscio, M. and Fratta, M.: Lack of effects of a lyposterolic extract of Serenoa repens on plasma levels of testosterone, follicle-stimulating hormone, and luteinizing hormone. Clin Ther, 10: 585, 1988
43. Di Silverio, F., D'Eramo, G., Lubrano, C. et al: Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients. Eur Urol, 21: 309, 1992
44. Vacher, P., Prevarskaya, N., Skyrma, R. et al: The lipidosterolic extract from Serenoa repens interferes with prolactin receptor signal transduction. J Biomed Sci, 2: 357, 1995
45. Paubert-Braquet, M., Cousse, H., Raynaud, J. P. et al: Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies. Eur Urol, 33: 340, 1998
46. Paubert-Braquet, M., Mencia Huerta, J. M., Cousse, H. et al: Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids, 57: 299, 1997
47. Krieg, M., Klotzl, G., Kaufmann, J. et al: Stroma of human benign prostatic hyperplasia: preferential tissue for androgen metabolism and oestrogen binding. Acta Endocrinol (Copenh), 96: 422, 1981
48. Goepel, M., Hecker, U., Krege, S. et al: Saw palmetto extracts potently and noncompetitively inhibit human alpha-1-adrenoceptors in vitro. Prostate, 38: 208, 1999
49. Sokeland, J. and Albrecht, J.: Kombination aus Sabal-und urticaextrakt vs. finasterid bei BPH (Stad. I bis II nach alken). Urologe A, 36: 327, 1997
50. Semino, M. A., Ortega, J. L. L., Cobo, E. G. et al: Tratamiento sintomatico de la hipertrofia benigna de prostata. Estudio comparative entre prazosin y Serenoa repens. Arch Esp Urol, 45: 211, 1992
51. Grasso, M., Montesano, A., Buonaguidi, A. et al: Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia. Arch Esp Urol, 48: 97, 1995
52. Chopin, D., Perier, A. and Raynaud, J. P.: Improvements in benign prostatic hypertrophy (BPH) symptoms are not related to prostatic volume in the Permixon/finasteride comparative study. Presented at the 4th International Consultation on BPH, Paris, France, 1997
53. Braeckman, J.: The extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a multicenter open study. Curr Ther Res, 55: 776, 1994
54. Descotes, J. L., Rambeaud, J. J., Deschaseaux, P. et al: Placebo-controlled evaluation of the efficacy and tolerability of Permixon in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Invest, 9: 291, 1995
55. Reece Smith, H., Memon, A., Smart, C. J. et al: The value of Permixon in benign prostatic hypertrophy. Br J Urol, 58: 36, 1986
56. Champault, G., Patel, J. C. and Bonnard, A. M..: A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. Br J Clin Pharmac, 18: 461, 1984
57. Champault, G., Bonnard, A. M., Cauquil, J. et al: Traitement medical de l'adenome prostatique. Ann Urol (Paris), 18: 407, 1984
58. Boccafoschi, C. and Annoscia, S.: Confronto fra estratto di Serenoa repens e placebo mediante prova clinica controllata in pazienti con adenomatosi prostatica. Urologia, 50: 1, 1983
59. Metzker, H., Kieser, M. and Holscher, U.: Wirdsamkeit eines Sabal-urtica-kombinationspraparats bei der behandlung der benignen prostathyperplasie (BPH). Urologe B, 36: 292, 1996
60. Tasca, A., Barulli, M., Cavazzana, A. et al: Trattamento della sintomatologia ostruttiva da adenoma prostatico con estratto di Serenoa repens. Minerva Urol Nefrol, 37: 87, 1985
61. Cukier, J., Ducassou, J., Le Guillou, M. et al: Permixon versus placebo. Results d'une etude multicentrique. C R Ther Pharmacol Clin, 4: 15, 1985
62. Emili, E., Lo Cigno, M. and Petrone, U.: Risultati clinic su un nuovo farmaco nelle terapia dell'ipertrofia della prostate (Permixon) Urologia, 50: 1042, 1983
63. Lowe, F., Robertson, C., Roehrborn, C. et al: Meta-analysis of clinical trials of Permixon. J Urol, suppl., 159: 257, abstract 986, 1998
64. Roehrborn, C. G.: BPH Clinical Research Criteria. In: Proceedings of the 4th International Consultation on Benign Prostatic Hyperplasia (BPH), 1997. Edited by L. Denis, K. Griffiths, S. Khoury et al: Plymouth, United Kingdom: Health Publication Ltd, pp. 437-514, 1998
65. Bailar, J. C.: The promise and problems of meta-analysis. N Engl J Med, 337: 559, 1997
66. Bailar, J. C.: The practice of meta-analysis. J Clin Epidemiol, 48: 149, 1995
67. LeLorier, J., Gregoire, G., Benhaddad, A. et al: Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med, 337: 536, 1997
68. Shapiro, S.: Is meta-analysis a valid approach to the evaluation of small effects in observational studies. J Clin Epidemiol, 50: 223, 1997
69. Dreikorn, K., Borkowski, A., Braeckman, J. et al: Other medical therapies. In: Proceedings of the 4th International Consultation on Benign Prostatic Hyperplasia (BPH), 1997. Edited by L. Denis, K. Griffiths, S. Khoury et al. Plymouth, United Kingdom: Health Publication Ltd., pp. 633-659, 1998